(Reuters) – AstraZeneca Plc may skip asking the U.S. Food and Drug Administration for emergency-use authorization for its COVID-19 vaccine, and instead pursue the more time-intensive application for a full-fledged license to sell the shot, the Wall Street Journal reported on Friday.
Such a step would further delay any rollout of the British drugmaker’s shots in the United States, according to the report https://on.wsj.com/3eWvrry, which cited people familiar with the matter.
(Reporting by Kanishka Singh in Bengaluru; Editing by Chris Reese)
